DE60036132D1 - Quantitative immunoenzymatische messmethode - Google Patents

Quantitative immunoenzymatische messmethode

Info

Publication number
DE60036132D1
DE60036132D1 DE60036132T DE60036132T DE60036132D1 DE 60036132 D1 DE60036132 D1 DE 60036132D1 DE 60036132 T DE60036132 T DE 60036132T DE 60036132 T DE60036132 T DE 60036132T DE 60036132 D1 DE60036132 D1 DE 60036132D1
Authority
DE
Germany
Prior art keywords
cetp
immunoenzymatic
quantitative
measurement method
plasma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60036132T
Other languages
English (en)
Other versions
DE60036132T2 (de
Inventor
Garcia Ana Lucia Alonso
Oliva Jaime Mas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universidad Nacional Autonoma de Mexico
Original Assignee
Universidad Nacional Autonoma de Mexico
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universidad Nacional Autonoma de Mexico filed Critical Universidad Nacional Autonoma de Mexico
Application granted granted Critical
Publication of DE60036132D1 publication Critical patent/DE60036132D1/de
Publication of DE60036132T2 publication Critical patent/DE60036132T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/11—Immunoglobulins specific features characterized by their source of isolation or production isolated from eggs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/23—Immunoglobulins specific features characterized by taxonomic origin from birds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE60036132T 1999-12-13 2000-12-13 Quantitative immunoenzymatische messmethode Expired - Lifetime DE60036132T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
MX9911575 1999-12-13
MX9911575 1999-12-13
PCT/MX2000/000053 WO2002032935A1 (es) 1999-12-13 2000-12-13 Metodo inmunoenzimatico para cuantificar

Publications (2)

Publication Number Publication Date
DE60036132D1 true DE60036132D1 (de) 2007-10-04
DE60036132T2 DE60036132T2 (de) 2008-08-21

Family

ID=19745132

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60036132T Expired - Lifetime DE60036132T2 (de) 1999-12-13 2000-12-13 Quantitative immunoenzymatische messmethode

Country Status (8)

Country Link
US (1) US7749721B2 (de)
EP (1) EP1242446B1 (de)
AT (1) ATE370971T1 (de)
AU (1) AU2234801A (de)
CA (1) CA2394670A1 (de)
DE (1) DE60036132T2 (de)
ES (1) ES2292493T3 (de)
WO (1) WO2002032935A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2636681A1 (de) 2012-03-09 2013-09-11 CSL Behring AG Verfahren zur Anreicherung von IgA
US10221233B2 (en) 2012-03-09 2019-03-05 Csl Behring Ag Compositions comprising secretory-like immunoglobulins
EP2636684A1 (de) * 2012-03-09 2013-09-11 CSL Behring AG Vorbeugung von Infektionen
MX347400B (es) 2012-06-29 2017-04-18 Univ Nac Autónoma De México Vacuna de aplicacion nasal contra el desarrollo de la enfermedad aterosclerotica y el higado graso.
WO2015190903A1 (es) * 2014-06-11 2015-12-17 Universidad Nacional Autonoma De Mexico Péptidos derivados del dominio c-terminal de cetpi como moléculas bloqueadoras del efecto citotóxico inducido por lipopolisacáridos en septicemia y choque séptico

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4975420A (en) * 1987-09-30 1990-12-04 University Of Saskatchewan Agents and procedures for provoking an immune response to GnRH and immuno sterilizing mammals
US5604105B1 (en) * 1990-10-12 1999-08-24 Spectral Diagnostics Inc Method and device for diagnosingand distinguishing chest pain in early onset thereof
ATE161543T1 (de) * 1992-01-31 1998-01-15 David Jeston Baylink Aminoterminale prokollagen 1(i) peptide
US5585235A (en) 1993-04-13 1996-12-17 Diagnescent Technologies, Inc. Fluorescent assay and method that corrects for spectral interference
US5705388A (en) * 1994-12-23 1998-01-06 Ribozyme Pharmaceuticals, Inc. CETP Ribozymes
US5631133A (en) * 1995-05-12 1997-05-20 The Regents Of The University Of California Transition in transcriptional activation by intracellular hormone receptors at the tumor stage of dermal fibrosarcoma development
US5801015A (en) * 1995-06-05 1998-09-01 Mitotix, Inc. Nucleic acid encoding a Candida cell cycle regulatory protein, TYP1 polypeptide
DE69626642T2 (de) * 1995-06-06 2004-01-29 Avant Immunotherapeutics Inc Cetp zur erhöhung des hdl-cholesterol-gehalts
EP1024825A1 (de) * 1997-10-20 2000-08-09 Avant Immunotherapeutics, Inc. Xenogenäisches cholesterylestertransferprotein (cetp) zur modulierung der cetp-aktivität

Also Published As

Publication number Publication date
EP1242446A1 (de) 2002-09-25
EP1242446B1 (de) 2007-08-22
CA2394670A1 (en) 2002-04-25
ES2292493T3 (es) 2008-03-16
DE60036132T2 (de) 2008-08-21
AU2234801A (en) 2002-04-29
US20030186342A1 (en) 2003-10-02
ATE370971T1 (de) 2007-09-15
US7749721B2 (en) 2010-07-06
WO2002032935A1 (es) 2002-04-25

Similar Documents

Publication Publication Date Title
WO2020123319A3 (en) Methods of using master / copy arrays for spatial detection
PE20001316A1 (es) Anticuerpo humanizado especifico para 4-1bb humano y composicion farmaceutica que lo contiene
ES2181674T3 (es) Dominios de union en las proteinas notch y delta.
ATE172743T1 (de) Nachweis von kollagenabbau -i(in vivo)
ATE230487T1 (de) Verfahren zur frühen diagnose von carcinomen
ATE464374T1 (de) Assay zum schnellen nachweis vom humanen aktivierten protein c und hochspezifischer monoklonaler antikörper dagegen
DE69937835D1 (de) Antikörper für apoptosemarker und anwendungsverfahren
EA202092087A1 (ru) Анализы для выявления нейродегенеративных заболеваний
CY1110461T1 (el) Αναλυση της τυποποιησης μονοκλωνικων πρωτεϊνων με τριχοειδη ηλεκτροφορηση και ανοσομετατοπιση
ATE489623T1 (de) Peptide zum nachweis von ehrlichia ewingii antikörper
BRPI0812875A2 (pt) " método pra identificar se ou não um indivíduo está sob risco de desenvolvimento de sépsis severa, anticorpo específico para proteína ligante de heparina, método pra reduzir o risco de um indivíduo desenvolver sépsis severa, e, kit de teste ".
DE60013320D1 (de) Analytassay-vorrichtung mit vorabsorbieren-zone
Zhang et al. SpeB proteolysis with imaged capillary isoelectric focusing for the characterization of domain-specific charge heterogeneities of reference and biosimilar Rituximab
Zampieri et al. The use of Tween 20 in immunoblotting assays for the detection of autoantibodies in connective tissue diseases
ATE258310T1 (de) Testverfahren für collagenpeptid
SE0000675D0 (sv) Monoclonal antibodies
FR2816410B1 (fr) Necessaire de detection de la proteine esm-1 et procede de detection mettant en oeuvre ledit necessaire
EA200401628A1 (ru) Ингибиторы пептидной деформилазы
DE60036132D1 (de) Quantitative immunoenzymatische messmethode
ID19063A (id) Pereaksi peptida untuk deteksi cytomegalovirus (cmv)
WO2004092741A3 (en) Mapping discontinuous antibody or aptamer epitopes for protein structure determination and other applications
DE60024809D1 (de) Verwendung von anti-hbp antikörper zur inhibierung der freisetzung von bradykinin
ATE282830T1 (de) Immuntest für human chromogranine a (cga), antikörper, reagenz und dazu geeigneter testsatz
WO2003107000A3 (de) Ermittlung der wechselwirkung zwischen c-reaktivem protein und an c-reaktives protein bindenden komponenten
DE60222149D1 (de) Referenzkontrolle für hochempfindliche tests des c-reaktiven proteins

Legal Events

Date Code Title Description
8332 No legal effect for de
8370 Indication related to discontinuation of the patent is to be deleted
8364 No opposition during term of opposition